U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Lung Adenocarcinoma

MedGen UID:
1791973
•Concept ID:
C5555532
•
Neoplastic Process

Definition

Lung adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Lung Adenocarcinoma

Professional guidelines

PubMed

Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, Bai YY, Cheng YZ, Nan KJ, Liang X
Drug Des Devel Ther 2015;9:6421-31. Epub 2015 Dec 14 doi: 10.2147/DDDT.S95606. PMID: 26715839Free PMC Article
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V, Losonczy G, Francovszky E, Tolnay E, Torok S, Galffy G, Hegedus B, Dome B, Ostoros G
Lung Cancer 2014 Oct;86(1):54-8. Epub 2014 Jul 27 doi: 10.1016/j.lungcan.2014.07.011. PMID: 25129367

Recent clinical studies

Etiology

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB
J Thorac Oncol 2012 Oct;7(10):1618-21. doi: 10.1097/JTO.0b013e318267d051. PMID: 22982661

Diagnosis

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.
Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, Yang N, Lei J, Chen X, Zeng L, Klein MA, Hoeppner LH
Oncogene 2022 Jan;41(1):83-98. Epub 2021 Oct 21 doi: 10.1038/s41388-021-02028-5. PMID: 34675407Free PMC Article
Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report.
Liu X, Liu H, Luo S
Medicine (Baltimore) 2018 Dec;97(49):e13427. doi: 10.1097/MD.0000000000013427. PMID: 30544423Free PMC Article
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA
Cancer Immunol Res 2015 Aug;3(8):855-63. Epub 2015 May 26 doi: 10.1158/2326-6066.CIR-15-0024. PMID: 26014096Free PMC Article

Therapy

Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor.
Chong KM, Yang CY, Lin CC, Lien WC
Am J Emerg Med 2022 Jun;56:395.e1-395.e3. Epub 2022 Mar 18 doi: 10.1016/j.ajem.2022.03.030. PMID: 35339338Free PMC Article
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G
Lung Cancer 2020 Aug;146:78-85. Epub 2020 May 21 doi: 10.1016/j.lungcan.2020.05.018. PMID: 32521388
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA
Cancer Immunol Res 2015 Aug;3(8):855-63. Epub 2015 May 26 doi: 10.1158/2326-6066.CIR-15-0024. PMID: 26014096Free PMC Article
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A
J Immunother 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237. PMID: 23994887Free PMC Article
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB
J Thorac Oncol 2012 Oct;7(10):1618-21. doi: 10.1097/JTO.0b013e318267d051. PMID: 22982661

Prognosis

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.
Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, Yang N, Lei J, Chen X, Zeng L, Klein MA, Hoeppner LH
Oncogene 2022 Jan;41(1):83-98. Epub 2021 Oct 21 doi: 10.1038/s41388-021-02028-5. PMID: 34675407Free PMC Article
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA
Cancer Immunol Res 2015 Aug;3(8):855-63. Epub 2015 May 26 doi: 10.1158/2326-6066.CIR-15-0024. PMID: 26014096Free PMC Article
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB
J Thorac Oncol 2012 Oct;7(10):1618-21. doi: 10.1097/JTO.0b013e318267d051. PMID: 22982661

Clinical prediction guides

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.
Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, Yang N, Lei J, Chen X, Zeng L, Klein MA, Hoeppner LH
Oncogene 2022 Jan;41(1):83-98. Epub 2021 Oct 21 doi: 10.1038/s41388-021-02028-5. PMID: 34675407Free PMC Article
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA
Cancer Immunol Res 2015 Aug;3(8):855-63. Epub 2015 May 26 doi: 10.1158/2326-6066.CIR-15-0024. PMID: 26014096Free PMC Article
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.
Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A
J Immunother 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237. PMID: 23994887Free PMC Article
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB
J Thorac Oncol 2012 Oct;7(10):1618-21. doi: 10.1097/JTO.0b013e318267d051. PMID: 22982661

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...